Currently available models of insulin dynamics are mostly based on the classical 25 compartmental structure and thus their physiological utility is limited. In this work, we 26 describe the development of a physiological-based model and its application to data from 27 154 patients who underwent an insulin-modified intravenous glucose tolerance test 28 (IM-IVGTT). In order to determine the time profile of endogenous insulin delivery 29 without using C-peptide data and to evaluate the transcapillary transport of insulin, the 30 hepatosplanchnic, renal and peripheral beds were incorporated into the circulatory model 31 as separate subsystems. Physiologically reasonable population mean estimates were 32 obtained for all estimated model parameters, including plasma volume, interstitial volume 33 of the peripheral circulation (mainly skeletal muscle), uptake clearance into the interstitial 34 space, hepatic and renal clearance, as well as total insulin delivery into plasma. 
INTRODUCTION 43 44
Insulin administration continues to be an important therapy in treating patients 45 with type 1 and also type 2 diabetes mellitus. Some newer classes of pharmacotherapies, 46 moreover, act by stimulating endogenous insulin secretion, including incretin analogues 47 and DPP-4 inhibitors (20) . Thus a more complete understanding of the pathophysiology 48 of insulin dynamics may lead to improved management of diabetes in patients treated 49
with insulin or with therapies that promote endogenous insulin release. 50
Insulin disposition in humans has been studied previously using compartmental 51 analysis to quantify the kinetic of insulin's distribution and elimination (see (6) for a 52 review). While such compartment models for insulin dynamics are useful for describing 53 plasma insulin concentration-time profiles (e.g., following intravenous, subcutaneous and 54 inhaled insulin administration), a drawback of the reported one (15), two (23) and three 55 (27) compartment mammillary models, including time varying (21) and nonlinear models 56 (16) , is that the model compartments have little anatomical and physiological 57 correspondence. As a consequence the model and its parameters cannot be readily 58 interpreted in terms of fundamental transport mechanisms that underlie the distribution 59 and elimination of insulin. For example, previously reported compartment models do not 60 provide information on the dynamics of insulin uptake by skeletal muscle tissue, yet such 61 information is valuable since muscle uptake of insulin is the rate-limiting step in insulin 62 stimulated muscle glucose uptake (1, 3). Moreover, the mechanism of this transport 63 process remains unclear (2, 18) . These compartment models, furthermore, do not readilykidney and other relevant diseases, and as such provide limited ability to reflect changes 66 in insulin disposition in disease progression. 67
To address the aforementioned limitations of current models of insulin dynamics, 68
we have developed a physiologically-based pharmacokinetic (PBPK) model for insulin 69 disposition using plasma glucose and insulin time course data from patients who 70 underwent a frequently sampled insulin modified-intravenous glucose tolerance test 71 (IM-IVGTT) to determine beta-cell function and insulin sensitivity (11, 29, 32, 37) . The 72 specific aims of the study were to use the insulin concentration data from the IM-IVGTT 73 test obtained in healthy females and in women at risk for developing diabetes to construct 74 a physiological-based circulatory model of insulin dynamics in humans as a tool which 75 will allow the evaluation of the uptake of insulin into the skeletal muscle, and the 76 estimation of both hepatic and renal clearance of insulin. 77 78 79
MATERIALS AND METHODS 80 81
Participants and Study Design. Women who previously exhibited gestational diabetes 82 (that is, who are at risk for developing diabetes) and women who had normal pregnancies 83 were recruited from the outpatient department of the University Clinic of Vienna. The 84 details of the clinical study, including the ethical committee's approvals, have been 85 reported elsewhere (37). A total of 120 who previously exhibited gestational diabetes and 86 34 women who had normal pregnancy had complete data and were used in the analysis 87 reported herein. The anthropometric characteristics of these 154 women are as follows:specific pattern has been assumed a priori as depicted in Fig. 1 . It is a simplified form of 113 I(t) profiles reported in the literature (10, 19) and consists of a supra basal phase 1 (peak) 114 rate lasting 3.5 min (I phase1 ) followed by a reduced phase 2 rate lasting 17 min (I phase1 /6). 115
Based on a well-mixed organ model, the intrinsic clearances CL int,L and CL int,K account 116 for hepatic extraction (metabolism) and renal elimination of insulin. The complete set of 117 equations describing the model shown in Fig. 1 is provided in the Appendix. Since all 118 patients were in a fasted state when the IM-IVGTT was initiated, the model was assumed 119 to be in steady state prior to glucose administration (see Appendix for further details). 120
In order to select the most parsimonious model of insulin distribution in the 121 peripheral circulation, the two-compartment tissue model was compared to both simpler 122 and more complex models. The alternate models included a one-compartment (flow 123 limited) distribution model, and a model with a saturable (Michaelis-Menten) uptake 124 process and lymphatic back-transport from the interstitial space to the venous pool. We 125 have neglected extraction since it was not possible to estimate separately insulin 126 clearance by the kidney and the rest of the peripheral circulation. Non-blood flow limited 127 models for the other organs and tissues were not supported by the experimental data of 128 the IM-IVGTT study used in the current work. 129
130
Parameter Estimation and Statistical Analysis. The insulin concentration-time data from 131 all patients were analyzed simultaneously using a hierarchical, population modeling 132 approach that allows information from the separate patients to collectively inform thewell as their precision as percent relative standard error (%RSE). Furthermore, estimates 136 of the individual subject parameters are available. The hierarchical analysis was 137 accomplished via maximum likelihood estimation using the expectation-maximization 138 algorithm (MLEM ) in the ADAPT (version 5) software for 139 pharmacokinetic/pharmacodynamic system analysis (8). Estimated model parameters 140
were assumed to follow a multivariate log-normal distribution and the error associated 141 with measured insulin was assumed to be normally distributed with standard deviation 142 dependent on insulin (additive and proportional error terms). Model selection for insulin 143 distribution was based on the resulting values of the Akaike Information Criterion (AIC) 144
for the tested models (as implemented in (8) Other relevant quantities were derived from the estimated and fixed model 151 parameters. For the one compartment liver model (see Fig. 1 
The total insulin delivery (TID ), i.e. the total amount of insulin delivered after hepatic 159 degradation, was calculated from the estimated delivery rate of insulin above basal as 160 Table 2 lists the estimated population mean estimates for
CL int,K , I basal and I phase1 , together with their inter subject variability, obtained using the 194 model shown in Fig. 1 (percent relative standard errors, %RSE, shown for each estimate). 195
The table also shows the resulting values of the derived quantities including the hepatic 196 clearance (CL hep ), renal clearance (CL ren ), hepatic extraction ratio (E hep (%)), total insulin 197 delivery (TI) and total insulin secretion (TIS), calculated based on the definitionspresented in the Materials and Methods section. The renal extraction ratio of 0.22 was for 199 a BW =70 kg, as determined using the value of renal flow in Table 1 and renal clearance  200 in Table 2 humans. In addition to the exogenous insulin infusion from the IM-IVGTT protocol, the 215 model accounts for the resulting endogenous post hepatic secretion of insulin (i.e., the 216 basal level and the response to glucose stimulation), and divides the systemic system into 217 three lumped subsystems: hepato-splanchnic, renal and remainder (largely skeletal 218 muscle). The latter was modeled by a vascular space compartment and an interstitial 219 space compartment with permeation controlled by the permeability surface areamuscle. The model allows for estimation of hepatic insulin clearance and extraction, and 222 an estimate of renal insulin clearance through the kidney subsystem included in the 223 model. 224
The IM-IVGTT study upon which the current modeling analysis is based was 225 designed for evaluating insulin sensitivity and not explicitly for the goal of modeling 226 insulin disposition. However, by using prior information for certain model parameters 227 (Table 1) , exploiting the information in the measured insulin data from both the glucose 228 and insulin administration portions of the IM-IVGTT protocol, and using a population clearance from the later disposition phase. To investigate the reliability of the estimated 237 skeletal muscle distribution parameters of the model (both population mean and 238 intersubject variability), the population analysis was also performed with intrinsic insulin 239 renal clearance fixed at 171 ml/min (the estimated value shown in Table 2 ) and at 243 240 holds also for the ratio of hepatic to peripheral clearance (28), assuming that renal 258 extraction is the main contribution to the latter. The estimated mean hepatic extraction 259 ratio of 46% is in accordance with values reported previously for humans (5, 6). The 260 estimated total clearance, CL hep +CL ren , of 504 ml/min is somewhat lower than that of 716 261 ml/min reported in a pharmacokinetic study (23), which could be attributed to different 262 subject populations and experiment designs. Note that the estimated parameter CL int,L is 263 independent of blood flow; CL hep is a derived parameter that is dependent on hepatic 264 blood flow (Eq. 1). 265 higher than the typical value of muscle blood volume reported for humans 12 ml/kg (17), 268 but this is not unexpected in that V 1 in the model includes not only skeletal muscle blood 269 volume but also that of other tissues of distribution. The V 2 estimate of 24.9 ml/kg 270 obtained in the modelling analysis is smaller than the muscle interstitial volume of 39 271 ml/kg reported in (4), and may be due to the endogenous insulin level leading to a less 272 well defined terminal insulin disposition phase. For the transendothelial insulin transport 273 into the interstitial space a permeability-surface product (or uptake clearance) of 75.8 274 ml/min was estimated (PS in the model), compared to a value of 105 ml/min measured 275 directly in human skeletal muscle using microdialysis (13 constant shape of insulin delivery rate assumed in the present work, the resulting 287 estimates of the underlying biphasic insulin secretion rates were within the range of 288 values reported previously for the same dose of glucose (0.3 g/kg) in humans. The modelestimate of the maximum rate of insulin delivery (I phase1 , first peak in Fig. 1 ) was 61.2 290 mU/min, which is within the wide range of 43 to 181 mU/min reported in (10), but higher 291 than that of 12 mU/min estimated by (31). The estimated basal delivery rate (I basal in Fig.  292 1) was 2.98 mU/min, which is lower than 7 mU/min reported in (22) and somewhat 293 higher than the value of 0.95 mU/min reported in (31). Note that the calculation of insulin 294 secretion (Eq. 4) is based on the assumption that insulin clearance is not saturated, as 295 required by Eq. 2. 296
297
The objective of the work reported herein was to develop a PBPK model of insulin 298 kinetics. To achieve this aim, given the clinical study design, it was necessary to assume 299 both a time-constant hepatic extraction and a piece-wise constant pattern of insulin 300 delivery as has been used previously (e.g., (34)). The simplified model used for insulin 301 release, while appropriate for the patient population under study, would not be applicable 302 more broadly as part of a complete IM-IVGTT model for other populations or study 303 designs. Despite these limitations, the resulting overall PBPK model includes parameters 304 representing the physiological properties that determine insulin disposition. We note that 305 other model-based approaches such as those based on an empirical description of insulin 306 disposition and C-peptide data allow the estimation of the time-dependence of extraction 307 and the pattern of insulin secretion (30, 31). Insulin release profiles so obtained, could 308 then be incorporated into the PBPK model for insulin disposition reported in this work. 309 310
In conclusion, the physiological-based model of insulin dynamics presented describes theAs a consequence of the model's physiological basis, it can be used to predict alterations 313 in insulin dynamics that might be expected in diabetic complications involving 314 cardiovascular system, as well as the liver and kidneys. Thus the model provides a 315 framework for incorporating disease progression into predictions of insulin dynamics that 316 may further inform insulin-based treatment of diabetes. Moreover, independent estimates 317 of the model's physiological parameters in individual subjects (e.g., noninvasive 318 estimates of cardiac output) can be used to improve the model's subject-specific 319 predictive ability. , 00
The form of IV(t) in the first equation above is depicted in Fig.1 . A run-in period isproduce the corresponding non-zero basal values of insulin in all tissues prior to the start 461 of the IM-IVGTT protocol (t=0 in Fig. 1 (17) 49 (9) 81 (22) Permeability-surface product PS (ml/min) 75.8 (13) 64 (21) Intrinsic hepatic clearance
Intrinsic renal clearance CL int,L (ml/min) CL int,K (ml/min)
571 (22) 171 (51) 67 (27) 65 ( 
